Psychiatry
Major Depressive Disorder
Clinical Topic Updates Podcast: The Evolution of Diagnostic Biomarkers and Neuroimaging in Depression
Despite decades of ongoing research, depression still lacks the widespread availability of reliable biomarkers to help guide diagnosis and treatment. Neuroimaging shows promise but remains impractical due to issues related to cost and access. Pharmacogenomic testing may offer only modest benefit for predicting treatment response, but it may be more useful for determining metabolism and toxicity risk. Inflammatory biomarkers have shown mixed results. As noted in today’s podcast, combining information from multiple types of biomarkers may hold the most promise for helping to predict patient outcomes.
Greden JF, Parikh SV, Rothschild AJ, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019;111:59-67. doi:10.1016/j.jpsychires.2019.01.003
Oslin DW, Lynch KG, Shih MC, et al. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME Care randomized clinical trial. JAMA. 2022;328(2):151-161. doi:10.1001/jama.2022.9805
Trivedi MH, McGrath PJ, Fava M, et al. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): rationale and design. J Psychiatr Res. 2016;78:11-23. doi:10.1016/j.jpsychires.2016.03.001
Williams LM, Rush AJ, Koslow SH, et al. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials. 2011;12:4. doi:10.1186/1745-6215-12-4
Explore More in Major Depressive Disorder
Major Depressive Disorder
The Role of Artificial Intelligence and Digital Psychiatry in Major Depressive Disorder Care
Major Depressive Disorder
Patient Care Perspectives Podcast: Structured Antidepressant Tapering and Support
Major Depressive Disorder